Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II gefitinib + fulvestrant in EGFR-mutated advanced NSCLC after prior reversible EGFR TKI failure
NL-OMON28300Phase 2Withdrawn
- Sponsor
- Vrije University Medical Center
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib and fulvestrant in non-small cell lung cancer (NSCLC), sponsored by Vrije University Medical Center. Primary endpoint: Non-progression rate at 8 weeks. Planned start Mar 2012; status: withdrawn.
02
Drugs
gefitinibfulvestrant
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON28300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28300.